Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- Generic Makers to Jointly Outsource GMP Inspections on Drug Substance Suppliers; Pilot to Begin by March
October 28, 2013
- Medwatcher Japan Calls for Legislation to Regulate Clinical Research in Wake of Diovan Scandal
October 28, 2013
- JPMA to Consider Information Disclosure on Provision of Labor to Research Institutes in Response to Diovan Scandal
October 28, 2013
- JMA Vice Pres. Nakagawa to Be Reinstated as CSIMC Member
October 25, 2013
- No Clear Violation of Fair Competition Code in Diovan Case: Maker FTC Exec
October 22, 2013
- JPMA Will Announce Response to Violation of PAL by Mitsubishi Tanabe in Near Future: Director General Goto
October 21, 2013
- Japan Self-Medication Industry’s Request Letter to Health Minister Factually Incorrect: JMA Exec
October 10, 2013
- Removal of JMA, JPA Members from OTC Drug Review Council, Open Discussion Would Be Difficult, Says JMA Exec
October 9, 2013
- Japan Self-Medication Industry Requests Health Minister to Remove JMA, JPA Members from OTC Drug Review Council
October 9, 2013
- Blanket 14-Day Prescription Limit Should Be Scrapped: EFPIA Japan Chair
October 8, 2013
- Diovan Issue is “Isolated Example,” Confidence in Japan Clinical Trials Not Lost: President Viehbacher of EFPIA
October 7, 2013
- JPMA Suspends Membership of Novartis Pharma in Response to Diovan Scandal
October 4, 2013
- JPMA Compliance Committee to Decide Penalties for Novartis for Diovan Case as Requested by Dr Teshirogi
October 3, 2013
- JGA Tells Members to Use Unified Trade Name “Losarhyd” for Generic Version of Combination Drug Preminent
October 1, 2013
- Generic Share Increases to 26.6% on Volume Basis in April-June 2013: JGA
October 1, 2013
- JSGM to Propose Incentive Dispensing Fee for Pharmacies That Carry Cheaper Generics, Unification of Premiums for Generic Dispensing Systems
September 26, 2013
- Japan, US Should Promote High Standards for Intellectual Property Protection and Pricing Transparency in TPP: PhRMA Executives
September 24, 2013
- JPMA Senior Managing Director Hiroaki Nakatani to Retire
September 17, 2013
- Transparency Guidelines: JPMA Says Requested Viewers’ Names, Affiliations Could Be Checked before Disclosing Individual Payment Information
September 13, 2013
- Wholesale Industry FTC Calls for Freeze on Efforts by Wholesalers to Refuse Free Services to Customers Due to Sharp Reactions from Some Pharmacies
September 4, 2013
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…